Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead 
Welcome,         Profile    Billing    Logout  
 50 Diseases   11 Trials   11 Trials   833 News 


«123456789101112»
  • ||||||||||  Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
    Journal:  Stimulation of the hepatic arterial buffer response using exogenous adenosine: hepatic rest/stress perfusion imaging. (Pubmed Central) -  Mar 23, 2021   
    Adenosine is already used clinically to stimulate myocardial blood flow in patients with suspected coronary disease, but the increase in flow did not correlate with the corresponding increase in hepatic arterial flow. • Analogous to the use of adenosine in the myocardium, the increase in hepatic arterial flow in response to adenosine has the potential to be a new clinically useful method for the evaluation of hepatic arterial haemodynamics in liver disease.
  • ||||||||||  Doburan (dobutamine) / VHB Life Sciences, Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead, Procoralan (ivabradine) / Amgen, Servier, Ono Pharma
    Review, Journal:  Practical instructions for using drugs in CT and MR cardiac imaging. (Pubmed Central) -  Mar 20, 2021   
    The progressive increase in numbers of noninvasive cardiac imaging examinations broadens the spectrum of knowledge radiologists are expected to acquire in the management of drugs during CT coronary angiography (CTCA) and cardiac MR (CMR) to improve image quality for optimal visualization and assessment of the coronary arteries and adequate MR functional analysis. Aim of this review is to provide an overview on different class of drugs (nitrate, beta-blockers, ivabradine, anxiolytic, adenosine, dobutamine, atropine, dipyridamole and regadenoson) that can be used in CTCA and CMR, illustrating their main indications, contraindications, efficacy, mechanism of action, metabolism, safety, side effects or complications, and providing advices in their use.
  • ||||||||||  Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
    Review, Journal:  Regadenoson Stress Testing: A Comprehensive Review With a Focused Update. (Pubmed Central) -  Mar 4, 2021   
    Although regadenoson has established safety and efficacy in most patients with chronic diseases, there are equivocal results in the literature for other chronic diseases. It is warranted to highlight that the use of regadenoson has not been studied in patients of low socioeconomic class; it is a condition that carries a significant burden on the cardiovascular system.
  • ||||||||||  Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
    Journal:  Deciphering the Agonist Binding Mechanism to the Adenosine A1 Receptor. (Pubmed Central) -  Feb 23, 2021   
    To date, no agonist other than the natural effector and the diagnostic regadenoson has been approved for human use...Here, we employed supervised molecular dynamics simulations and mutagenesis experiments to extend the structural knowledge of the binding of selective agonists to AR. Our results identify new residues involved in the association and dissociation pathway, they suggest the binding mode of N-cyclopentyladenosine (CPA) related ligands, and they highlight the dramatic effect that chemical modifications can have on the overall binding mechanism, paving the way for the rational development of a structure-kinetics relationship of AR agonists.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Phase classification, Trial completion date, Trial primary completion date:  Stress Testing and Cardiac Magnetic Resonance (clinicaltrials.gov) -  Feb 21, 2021   
    P4,  N=525, Recruiting, 
    Our results identify new residues involved in the association and dissociation pathway, they suggest the binding mode of N-cyclopentyladenosine (CPA) related ligands, and they highlight the dramatic effect that chemical modifications can have on the overall binding mechanism, paving the way for the rational development of a structure-kinetics relationship of AR agonists. Phase classification: P=N/A --> P4 | Trial completion date: Apr 2020 --> Apr 2035 | Trial primary completion date: Apr 2020 --> Apr 2030
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  ArmCrank: Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome (clinicaltrials.gov) -  Feb 21, 2021   
    P=N/A,  N=133, Terminated, 
    Phase classification: P=N/A --> P4 | Trial completion date: Apr 2020 --> Apr 2035 | Trial primary completion date: Apr 2020 --> Apr 2030 N=300 --> 133 | Trial completion date: Jun 2023 --> Feb 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2023 --> Feb 2021; Terminated by the local IRB
  • ||||||||||  Doburan (dobutamine) / VHB Life Sciences, Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
    Journal:  Considerations for Stress Testing Performed in Conjunction with Myocardial Perfusion Imaging. (Pubmed Central) -  Feb 9, 2021   
    This article was prepared to focus on considerations for performing stress (exercise and pharmacologic) testing in conjunction with MPI. It is meant to: 1) provide a basic overview of the principles of exercise stress testing, 2) discuss indications, contraindication, patient preparation and protocols for exercise stress testing, 3) discuss the contraindications administration protocols and side effects for performing vasodilator (adenosine, dipyridamole and regadenoson) stress testing and 4) discuss the contraindications, administration protocols, and side effects for performing dobutamine stress testing.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial initiation date:  The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI (clinicaltrials.gov) -  Feb 4, 2021   
    P=N/A,  N=30, Not yet recruiting, 
    It is meant to: 1) provide a basic overview of the principles of exercise stress testing, 2) discuss indications, contraindication, patient preparation and protocols for exercise stress testing, 3) discuss the contraindications administration protocols and side effects for performing vasodilator (adenosine, dipyridamole and regadenoson) stress testing and 4) discuss the contraindications, administration protocols, and side effects for performing dobutamine stress testing. Initiation date: Nov 2020 --> May 2021
  • ||||||||||  Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
    [VIRTUAL] Pharmacologic stress test agents: a comparative adverse events profile () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_3477;    
    MPI is generally safe and well-tolerated, there were no severe adverse events seen in any group which resulted in terminating the test. Dipyridamole offers a safe and cost-effective alternative to regadenoson and adenosine for cardiac imaging studies.
  • ||||||||||  Neupogen (filgrastim) / Kyowa Hakko Kirin, Roche, Amgen
    [VIRTUAL] Optimizing medication use to decrease wholesale acquisition cost (WAC) purchases in a five-hospital health system () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_2280;    
    These medications included: IVIG, sugammadex, rabies immune globulin, dexmedetomidine, vasopressin, carboprost, desmopressin, albumin, remifentanil, glucagon, methylene blue, calcium gluconate, regadenoson, hydralazine, and filgrastim. Each medication is being evaluated for dose optimization, waste reduction, and site of care restriction opportunities to decrease WAC spend.
  • ||||||||||  neladenoson (BAY 1067197) / Bayer, Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
    Journal:  More Purinergic Receptors Deserve Attention as Therapeutic Targets for the Treatment of Cardiovascular Disease. (Pubmed Central) -  Nov 26, 2020   
    The P2YR antagonists such as clopidogrel, ticagrelor, and others are the most successful class of purinergic drugs targeting platelets for the treatment of acute coronary syndrome...The partial AR agonist neladenoson and the AR agonist regadenoson have been applied in cardiovascular medicine...The present review discusses the promising purinergic drugs used in clinical studies for the treatment of cardiovascular disease. We also update experimental evidence for many other PRs that can be considered as therapeutic targets for future drug development.
  • ||||||||||  Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
    Clinical, Journal:  Regadenoson in heart transplant recipients: Use without worries. (Pubmed Central) -  Nov 12, 2020   
    We also update experimental evidence for many other PRs that can be considered as therapeutic targets for future drug development. No abstract available
  • ||||||||||  Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
    [VIRTUAL] Rescuing Cardiac Dysfunction Following Traumatic Haemorrhagic Injury () -  Nov 6, 2020 - Abstract #AHA2020AHA_6243;    
    It also significantly reduced infiltration of neutrophils and apoptotic myocardial injury (0.5±0.1% vs 0.8±0.3 Ly6G, p=0,038 and 0.63 ±0.24% vs 2.50 ± 1.17 % Caspase 3, p = 0.0224). In conclusion, the administration of regadenoson during resuscitation improves physiological outcomes, alleviating trauma-induced cardiac injury and impacting positively on survival.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    New P1/2 trial:  Treat COVID-19 Patients With Regadenoson (clinicaltrials.gov) -  Oct 27, 2020   
    P1/2,  N=40, Not yet recruiting, 
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion date:  Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT (clinicaltrials.gov) -  Oct 21, 2020   
    P=N/A,  N=15, Active, not recruiting, 
    In conclusion, the administration of regadenoson during resuscitation improves physiological outcomes, alleviating trauma-induced cardiac injury and impacting positively on survival. Trial completion date: Mar 2020 --> Oct 2021
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Review, Journal:  Blood-Brain Barrier Disruption in Neuro-Oncology: Strategies, Failures, and Challenges to Overcome. (Pubmed Central) -  Oct 20, 2020   
    Among 35 registered trials relevant to BBBD in neuro-oncology in the ClinicalTrials.gov database, mannitol was the most common drug-based method, followed by RMP-7 and regadenoson...Based on shared challenges among all methods, our second objective is to discuss strategies for confirmation of BBBD, choice of systemic agent and drug design, alignment of BBBD method with real-world clinical workflow, and consideration of inadvertent toxicity associated with disrupting an evolutionarily-refined barrier. Finally, we conclude with a strategic proposal to approach future studies assessing BBBD.
  • ||||||||||  Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
    [VIRTUAL] Derangements in Cardiac Oxidative Metabolism in Humans With Dilated Cardiomyopathy (OnDemand) -  Oct 10, 2020 - Abstract #AHA2020AHA_4869;    
    However, this impairment was not quantitatively related to impaired myocardial perfusion reserve. Of the various mechanisms that could explain decrease in oxidative metabolism in DCM, these data suggest that reduced myocardial perfusion is not the principal driver of impaired oxidative metabolism.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion date:  Heart Rate Response to Regadenoson and Sudden Cardiac Death (clinicaltrials.gov) -  Sep 28, 2020   
    P=N/A,  N=90, Active, not recruiting, 
    Even low serum caffeine levels reduce quantitative perfusion during vasodilatory stress with false positive or false negative results minimized by empathic instruction, CFC analysis or repeat PET after strict caffeine abstention for definitive individualized risk stratification and management. Trial completion date: Jun 2020 --> Jun 2021
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion date, Trial primary completion date:  Simultaneous Assessment of FFR and SPECT (clinicaltrials.gov) -  Sep 4, 2020   
    P=N/A,  N=50, Recruiting, 
    These observations have the potential of important management and prognostic implications respectively. Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2020 --> Dec 2021
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead, NN1213 / Novo Nordisk
    Enrollment change, Trial withdrawal:  Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging (clinicaltrials.gov) -  Sep 4, 2020   
    P=N/A,  N=0, Withdrawn, 
    Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2020 --> Dec 2021 N=20 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial initiation date:  The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI (clinicaltrials.gov) -  Aug 30, 2020   
    P=N/A,  N=30, Not yet recruiting, 
    N=20 --> 0 | Recruiting --> Withdrawn Initiation date: Jul 2020 --> Nov 2020
  • ||||||||||  Lexiscan (regadenoson) / Astellas, GE Healthcare, Gilead
    Journal:  Regadenoson long-lasting use induced tachyarrythmia. (Pubmed Central) -  Aug 23, 2020   
    HRR may be a valuable tool in the risk assessment of RT candidates. No abstract available